Editas reports early-stage data from two patients in sickle cell disease
One company is moving forward in its bid to make a cell therapy for sickle cell disease viable — and after previous setbacks, including a hold earlier this year, execs are touting some really early data.
Editas Medicine announced Tuesday morning that it had positive safety and efficacy data from two patients in a Phase I/II trial investigating EDIT-301, a cell therapy candidate that Editas developed. Safety was measured in both patients, and efficacy data are from only the first patient dosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.